Ausria 2 125

Hematological indicators were measured using a hematology analyzer (UniCel DxH 800; Beckman Coulter, Brea, CA, USA). Biochemical indicators included fasting plasma glucose, hemoglobin A1c (HbA1c), serum uric acid, total cholesterol, triglyceride levels, high density lipoprotein-cholesterol (HDL-C); low density lipoprotein-cholesterol(LDL-C), aspartate aminotransferase, alanine aminotransferase, GGT, and alkaline phosphatase levels. All serum biochemical markers were measured using a Hitachi 7600 Automatic Biochemical Analyzer (Hitachi, Tokyo, Japan). Serum HbA1c levels were analyzed using a Premier Hb9210 HbA1c Analyzer (Bray, Ireland, Kansas City, MO, USA). Hepatitis B surface antigen was measured using radioimmunoassay kits (Ausria II-125; Abbott Laboratories, North Chicago, IL, USA) and anti-hepatitis C antibody was measured using a microparticle enzyme immunoassay (Ax SYM HCV III; Abbott Laboratories). All blood samples were obtained after an 8-h overnight fast.
The overall dataset (n = 2325) was randomly divided into two groups: the training dataset (n = 1162) and validation cohort (n = 1163).

HBV DNA levels were measured using Abbott Real Time HBV assays (Abbott Molecular Inc, Des Plaines, IL, USA) with a lower detection limit of 10 IU/mL. HBV genotype and genotypic resistance were determined by direct DNA sequencing (SeqHepB; Abbott Diagnostics, Lake Forest, IL, USA). The qHBsAg level was measured using Architect QT immunoassays (Abbott Diagnostic, Wiesbaden, Germany). Serum HBsAg, HBeAg, and anti-hepatitis B e antibody (anti-HBe Ab) were measured using radioimmunoassay kits (Ausria II-125; Abbott Laboratories, North Chicago, IL, USA). Hematological and biochemical parameters, including serum creatinine, were measured using automatic analyzers in a central laboratory in our hospital.